1620 Investment Advisors, Inc. Astria Therapeutics, Inc. Transaction History
1620 Investment Advisors, Inc.
- $142 Million
- Q3 2025
A detailed history of 1620 Investment Advisors, Inc. transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, 1620 Investment Advisors, Inc. holds 2,000 shares of ATXS stock, worth $25,020. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,000
Previous 2,000
-0.0%
Holding current value
$25,020
Previous $10,000
40.0%
% of portfolio
0.01%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding ATXS
# of Institutions
113Shares Held
51MCall Options Held
6.6KPut Options Held
0-
Perceptive Advisors LLC New York, NY6.49MShares$81.1 Million1.53% of portfolio
-
Vestal Point Capital, LP New York, NY4.52MShares$56.6 Million1.28% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.11MShares$51.4 Million6.34% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$44.5 Million5.84% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$44 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $190M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...